Methods Adults ( 18 years old) in a US claims database with a claim indicating initiation of either semaglutide or a DPP4i (index date) during the index period (1 January 201830 September 2020), a diagnosis code for T2D on or before the index date and at least 12 months continuous enrolment in the database pre-index were included and propensity score matched 1:1 on baseline demographic and clinical characteristics

One should not use AOD-9604 if they: Are pregnant or breastfeeding Are a minor Have a current or recent history of cancer (particularly hormone-sensitive cancers) Have uncontrolled diabetes or significant insulin resistance Have active thyroid disease that is not well-managed Are taking medications that may interact with peptide therapy (discuss with your provider) Have a known hypersensitivity to peptide compounds Comprehensive labs including metabolic panel, fasting glucose, HbA1c, thyroid panel, lipid panel, and hormone levels should be run before starting any peptide therapy and monitored regularly throughout
The Nerve Protection Factor Beyond tissue repair, BPC-157 demonstrates neuroprotective properties
Medical weight loss is a medically supervised, nonsurgical weight loss solution for individuals who want assistance with more than just diet and exercise to reduce weight
This collection includes provider-prescribed treatment options such as semaglutide and tirzepatide formulations for eligible patients seeking medically supervised weight management support
Complex and simple clinical reaction times are associated with gait, balance, and major fall injury in older subjects with diabetic peripheral neuropathy